Soluble interleukin-2-receptor and interleukin-6 changes during low-dose methotrexate treatment in rheumatoid arthritis.
Spadaro
A
A
Riccieri
V
V
Sili Scavalli
A
A
Sensi
F
F
Taccari
E
E
Zoppini
A
A
D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000187:drug effects / Q000378:metabolism*; D012995:Solubility
D018501:Antirheumatic Agents; D007376:Interleukin-2; D015850:Interleukin-6; D015375:Receptors, Interleukin-2; D008727:Methotrexate